coronavirus

Myocarditis in children, the coordinator of the Italian CTS (Scientific Technical Committee) recalls: "Not all children who died of Covid had serious concomitant diseases. The benefit-risk ratio of the vaccine is also favourable in the 5-11…

Emergency use of Merck's anti-Covid drug: European Agency's decision following UK green light

The next step after a vaccine: Molnupiravir, produced by the pharmaceutical company Msd, is to be taken twice a day in pill form

Russia, 40,443 new Covid cases registered in the last 24 hours

Effectiveness of the third dose of the Covid vaccine: "the booster dose of the Covid vaccine prevents with 92% protection against severe disease", according to a very large Israeli study just published in The Lancet

Myocarditis: Ema has asked companies marketing these vaccines to carry out a thorough review of all published data

The European Medicines Agency Ema explains that administering the vaccine six to eight months after the second dose promotes an increase in antibodies. However, the decision remains a national competence

New Covid vaccine: pharmaceutical company KM Biologics Co. will make the serum, "which has an extremely high level of safety," available in early 2022. It will be used for third doses

Covid in UK, highest number since 17 July. There have been 115 deaths. More than 300,000 new infections in the last week, but Johnson says: 'No plan B'

Covid and HIV, the turning point is in monoclonal antibodies? New therapeutic horizons were discussed during the 13th edition of the Icar Congress - Italian Conference on Aids and Antiviral Research